Related Experiment Video
Updated: Jul 19, 2026
07:50
Assay Development for High-Throughput Drug Screening Against Mycobacteria
Published on: October 25, 2024
Treatment for mycobacterial infections
1Liverpool School of Tropical Medicine, Liverpool, UK.
Current Opinion in Infectious Diseases
|October 13, 2006
Summary
Isoniazid monotherapy is effective for preventing tuberculosis (TB) in HIV patients. This finding is based on three new randomized, placebo-controlled trials, offering a significant advancement in managing HIV-associated TB.
Area of Science:
- Infectious Diseases
- Public Health
- Clinical Medicine
Background:
- Mycobacterium tuberculosis is a leading global cause of mycobacterial disease.
- Managing tuberculosis (TB) in HIV-infected individuals remains challenging, especially in resource-limited areas.
- Recent World Health Organization guidelines emphasize consistent treatment delivery, adherence, and practice audits for TB management.
Purpose of the Study:
- To evaluate the efficacy of isoniazid monotherapy as preventive therapy for HIV-associated tuberculosis.
- To highlight significant advancements in the clinical management of co-infected patients.
Main Methods:
- Publication of three new randomized, placebo-controlled trials.
- Analysis of clinical trial data on isoniazid preventive therapy.
Main Results:
- Established the efficacy of isoniazid monotherapy for preventive therapy in HIV-associated TB.
- Demonstrated a significant development in managing co-infections.
Conclusions:
- Isoniazid monotherapy is a viable and effective preventive strategy for individuals with HIV and TB.
- This finding represents a major step forward in addressing HIV-associated tuberculosis, particularly in resource-poor settings.
Related Concept Videos
01:28Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:26Pulmonary Tuberculosis IV
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
01:29Pulmonary Tuberculosis I
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:23Tuberculosis
Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...
01:28Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:27Cryptococcal Meningitis
Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...